**Supplementary file 3: References of Included studies**

**Title**: Adherence to Country-specific Guidelines among Economic Evaluations undertaken in three High-Income and Middle-Income Countries: A Systematic Review

**Authors**: Deepshikha Sharma1, Arun Kumar Aggarwal1, Thomas Wilkinson2, Wanrudee Isaranuwatchai3,4,5, Akashdeep Singh Chauhan1 Shankar Prinja1\*

**CANADA : 44 studies**

1. Allen L, John-Baptiste A, Meyer M, Richardson M, Speechley M, Ure D, Markle-Reid M, Teasell R. Assessing the impact of a home-based stroke rehabilitation programme: a cost-effectiveness study. Disabil Rehabil. 2019 Aug;41(17):2060-2065. doi: 10.1080/09638288.2018.1459879. Epub 2018 Apr 10. PMID: 29631453.
2. Asgar AW, Pighi M, Millan X, Khan R, Dorval JF, Ibrahim R, Azzalini L, Bonan R. Cost consequence analysis of use of a balloon expandable vascular access system and standard vascular sheath for transcatheter aortic valve implantation. Journal of Medical Economics. 2018 Nov 2;21(11):1091-5.
3. Atwood M, Beausoleil L, Breton MC, Laferriere C, Sato R, Weycker D. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Canadian Journal of Public Health. 2018 Dec 1;109(5-6):756-68.
4. Bansback N, Guh D, Oviedo‐Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, Anis AH. Cost‐effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018 Jul;113(7):1264-73.
5. Beilman CL, Kirwin E, Ma C, McCabe C, Fedorak RN, Halloran B, Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn’s Disease Reduces Costs Compared With Late Initiation, Clinical Gastroenterology and Hepatology (2018), doi: 10.1016/j.cgh.2018.07.032
6. Boodoo C, Perry JA, Cross KM, Isaranuwatchai W. Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model. CMAJ open. 2018 Oct;6(4):E486.
7. Buse GL, Manns B, Lamy A, Guyatt G, Polanczyk CA, Chan MT, Wang CY, Villar JC, Sigamani A, Sessler DI, Berwanger O. Troponin T monitoring to detect myocardial injury after noncardiac surgery: a cost–consequence analysis. Canadian Journal of Surgery. 2018 Jun;61(3):185.
8. Campbell PM, Corneau E, Nishimura D, Teng E, Ekoualla D. Cost-benefit analysis for a lead wheel weight phase-out in Canada. Science of the Total Environment. 2018 Oct 1;637:79-90.
9. Coyle K, Coyle D, Nault I, Parkash R, Healey JS, Gray CJ, Gardner MJ, Sterns LD, Essebag V, Hruczkowski T, Blier L. Cost effectiveness of ventricular tachycardia ablation versus escalation of antiarrhythmic drug therapy: the VANISH trial. JACC: Clinical Electrophysiology. 2018 May 1;4(5):660-8.
10. Crawford EJ, Pincus D, Camp MW, Coyte PC. Cost savings of implementing the SickKids Paediatric Orthopaedic Pathway for proximal humerus fractures in Ontario, Canada. Paediatrics & Child Health. 2018 Aug 16;23(6):e109-16.
11. Djalalov S, Masucci L, Isaranuwatchai W, Evans W, Peter A, Truscott R, Cameron E, Mittmann N, Rabeneck L, Chan K, Hoch JS. Economic evaluation of smoking cessation in Ontario's regional cancer programs. Cancer medicine. 2018 Sep;7(9):4765-72.
12. Elliott J, McCoy B, Clifford T, Wells GA, Coyle D. Economic evaluation of stiripentol for Dravet syndrome: a cost-utility analysis. Pharmacoeconomics. 2018 Oct 1;36(10):1253-61.
13. Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgery as initial therapy for patients with moderate‐to‐severe benign prostate hyperplasia: a cost‐effectiveness analysis. BJU international. 2018 Nov;122(5):879-88.
14. Ezeife DA, Kirk V, Chew DS, Nixon NA, Lee R, Le LW, Chan KK, Leighl NB. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer. 2018 Nov 1;125:1-7.
15. Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1840-1849.e16. doi: 10.1016/j.cgh.2018.12.018. Epub 2018 Dec 20. PMID: 30580095.
16. Health Quality Ontario. Magnetic resonance-guided focused ultrasound neurosurgery for essential tremor: a health technology assessment. Ontario health technology assessment series. 2018;18(4):1.
17. Health Quality Ontario. Cognitive behavioural therapy for psychosis: a health technology assessment. Ontario health technology assessment series. 2018;18(5):1.
18. Health Quality Ontario. Bilateral cochlear implantation: a health technology assessment. Ontario health technology assessment series. 2018;18(6):1.
19. Health Quality Ontario. Remote monitoring of implantable cardioverter-defibrillators, cardiac resynchronization therapy and permanent pacemakers: a health technology assessment. Ontario health technology assessment series. 2018;18(7):1.
20. Health Quality Ontario. Structured Education and Neuromuscular Exercise Program for Hip and/or Knee Osteoarthritis: A Health Technology Assessment. Ontario health technology assessment series. 2018;18(8):1.
21. Hiremath S, Akbari A, Wells GA, Chow BJ. Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis. International urology and nephrology. 2018 Aug 1;50(8):1477-82.
22. Kadatz M, Klarenbach S, Gill J, Gill JS. Cost‐effectiveness of using kidneys from hepatitis C nucleic acid test–positive donors for transplantation in hepatitis C–negative recipients. American Journal of Transplantation. 2018 Oct;18(10):2457-64.
23. Lathia N, Sullivan K, Tam K, Brna M, MacNeil P, Saltmarche D, Agro K. Cost-minimization analysis of community pharmacy-based point-of-care testing for strep throat in 5 Canadian provinces. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada. 2018 Sep;151(5):322-31.
24. Le A, Thavorn K, Lasso A, Kilty SJ. Economic evaluation of floseal compared to nasal packing for the management of anterior epistaxis. The Laryngoscope. 2018 Aug;128(8):1778-82.
25. Lee TC, Kaouache M, Grover SA. Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. CMAJ open. 2018 Apr 3;6(2):E162-7.
26. Luo FY, Crawford S, Drouin O, Chadha R. Can we predict and prevent emergency department visits for postpartum hypertensive complications in patients with hypertensive disorders in pregnancy?. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2018 Dec 17:1.
27. McClean S, Baerg K, Smith-Fehr J, Szafron M. Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis. CMAJ open. 2018 Jul;6(3):E285.
28. Mitchell D, Guertin JR, Dubois A, Dubé MP, Tardif JC, Iliza AC, Fanton-Aita F, Matteau A, LeLorier J. A discrete event simulation model to assess the economic value of a hypothetical pharmacogenomics test for statin-induced myopathy in patients initiating a statin in secondary cardiovascular prevention. Molecular Diagnosis & Therapy. 2018 Apr 1;22(2):241-54.
29. Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GG, Heng D, Soulières D, Reaume MN, Basappa N. Cost-utility of sunitinib versus pazopanib in metastatic renal cell carcinoma in canada using real-world evidence. Clinical drug investigation. 2018 Dec 1;38(12):1155-65.
30. Olthuis JV, McGrath PJ, Cunningham CE, Boyle MH, Lingley-Pottie P, Reid GJ, Bagnell A, Lipman EL, Turner K, Corkum P, Stewart SH. Distance-delivered parent training for childhood disruptive behavior (Strongest Families™): a randomized controlled trial and economic analysis. Journal of abnormal child psychology. 2018 Nov 1;46(8):1613-29.
31. Pechlivanoglou P, Paulden M, Pham B, Wong J, Horn SD, Krahn M. Turning High‐Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long‐Term Care. Journal of the American Geriatrics Society. 2018 Jul;66(7):1409-14.
32. Pharmacoeconomic Review Report: Tocilizumab (Actemra): (Hoffman-La Roche Limited): Indication: For the treatment of giant cell arteritis (GCA) in adult patients [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr. PMID: 30480923.
33. Robin P, Kumar S, Salaun PY, Le Roux PY, Couturaud F, Planquette B, Merah A, Roy PM, Thavorn K, Le Gal G. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis research. 2018 Nov 1;171:97-102.
34. Sarfaty M, Hall PS, Chan KK, Virik K, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA. Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer. European urology. 2018 Jul 1;74(1):57-62.
35. Shamout S, Nazha S, Dragomir A, Campeau L. A cost‐utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspective. Neurourology and urodynamics. 2018 Sep;37(7):2195-203.
36. Sutherland JM, Mok J, Liu G, Crump T, Wing K, Younger A, Penner M, Veljkovic A. Cost-utility study of the economics of bunion correction surgery. Foot & ankle international. 2018 1:7.
37. Tam DY, Hughes A, Fremes SE, Youn S, Hancock-Howard RL, Coyte PC, Wijeysundera HC. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. The Journal of thoracic and cardiovascular surgery. 2018 May 1;155(5):1978-88.
38. Tam DY, Hughes A, Wijeysundera HC, Fremes SE. Cost-effectiveness of self-expandable transcatheter aortic valves in intermediate-risk patients. The Annals of thoracic surgery. 2018 Sep 1;106(3):676-83.
39. Tarride JE, Quinn FR, Blackhouse G, Sandhu RK, Burke N, Gladstone DJ, Ivers NM, Dolovich L, Thornton A, Nakamya J, Ramasundarahettige C, Frydrych PA, Henein S, Ng K, Congdon V, Birtwhistle RV, Ward R, Healey JS. Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older? Can J Cardiol. 2018 Nov;34(11):1522-1525. doi: 10.1016/j.cjca.2018.05.016. Epub 2018 Jun 21. PMID: 30144961.
40. Wallner K, Pedroza RG, Awotwe I, Piret JM, Senior PA, Shapiro AJ, McCabe C. Stem cells and beta cell replacement therapy: a prospective health technology assessment study. BMC endocrine disorders. 2018 Dec 1;18(1):6.
41. Weeks CA, Marsh JD, MacDonald SJ, Graves S, Vasarhelyi EM. Patellar resurfacing in total knee arthroplasty: a cost-effectiveness analysis. The Journal of arthroplasty. 2018 Nov 1;33(11):3412-5.
42. Welk B, Isaranuwatchai W, Krassioukov A, Husted Torp L, Elterman D. Cost-effectiveness of hydrophilic-coated intermittent catheters compared with uncoated catheters in Canada: a public payer perspective. Journal of medical economics. 2018 Jul 3;21(7):639-48.
43. Yuen T, Carter MT, Szatmari P, Ungar WJ. Cost-effectiveness of genome and exome sequencing in children diagnosed with autism spectrum disorder. Applied health economics and health policy. 2018 Aug 1;16(4):481-93.
44. Yuen T, Carter MT, Szatmari P, Ungar WJ. Cost-effectiveness of universal or high-risk screening compared to surveillance monitoring in autism spectrum disorder. Journal of autism and developmental disorders. 2018 Sep 1;48(9):2968-79.

**SOUTH AFRICA: 79 studies**

1. Akudibillah G, Pandey A, Medlock J. Maximizing the benefits of ART and PrEP in resource-limited settings. Epidemiol Infect. 2017 Apr;145(5):942-956. doi: 10.1017/S0950268816002958. Epub 2016 Dec 29. PMID: 28031062; PMCID: PMC5861504.
2. Azman AS, Golub JE, Dowdy DW. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Med. 2014 Oct 30;12:216. doi: 10.1186/s12916-014-0216-0. PMID: 25358459; PMCID: PMC4224697.
3. Basu S, Shankar V, Yudkin JS. Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. The Lancet Diabetes & Endocrinology. 2016 Nov 1;4(11):922-32.
4. Bango F, Ashmore J, Wilkinson L, van Cutsem G, Cleary S. Adherence clubs for long‐term provision of antiretroviral therapy: cost‐effectiveness and access analysis from Khayelitsha, South Africa. Tropical Medicine & International Health. 2016 Sep;21(9):1115-23.
5. Bershteyn A, Klein DJ, Eckhoff PA. Age-targeted HIV treatment and primary prevention as a 'ring fence' to efficiently interrupt the age patterns of transmission in generalized epidemic settings in South Africa. Int Health. 2016 Jul;8(4):277-85. doi: 10.1093/inthealth/ihw010. Epub 2016 Mar 23. PMID: 27008897; PMCID: PMC4967845.
6. Campos NG, Lince-Deroche N, Chibwesha CJ, Firnhaber C, Smith JS, Michelow P, Meyer-Rath G, Jamieson L, Jordaan S, Sharma M, Regan C, Sy S, Liu G, Tsu V, Jeronimo J, Kim JJ. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):195-205. doi: 10.1097/QAI.0000000000001778. PMID: 29916959; PMCID: PMC6143200.
7. Chiu C, Johnson LF, Jamieson L, Larson BA, Meyer-Rath G. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 Jan 31;17(1):143. doi: 10.1186/s12889-017-4023-3. PMID: 28143525; PMCID: PMC5282636.
8. Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, Walensky RP, Essajee S, Losina E, Muhe L, Wools-Kaloustian K, Ayaya S, Weinstein MC, Palumbo P, Freedberg KA. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS. 2015 Jun 19;29(10):1247-59. doi: 10.1097/QAD.0000000000000672. PMID: 25870982; PMCID: PMC4536981.
9. Ciaranello AL, Myer L, Kelly K, Christensen S, Daskilewicz K, Doherty K, Bekker LG, Hou T, Wood R, Francke JA, Wools-Kaloustian K, Freedberg KA, Walensky RP. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis. PLoS One. 2015 Mar 10;10(3):e0117751. doi: 10.1371/journal.pone.0117751. PMID: 25756498; PMCID: PMC4355621.
10. Custer B, Janssen MP, Hubben G, Vermeulen M, van Hulst M. Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV, HCV and HBV. Vox Sanguinis. 2017 Aug;112(6):526-34.
11. de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine. 2018 Feb 8;36(7):997-1007. doi: 10.1016/j.vaccine.2017.12.073. Epub 2018 Jan 17. PMID: 29373192; PMCID: PMC5805858.
12. De Jager P, Zungu M, Dyers RE. Economic evaluation of safety-engineered devices and training in reducing needlestick injuries among healthcare workers in South Africa. S Afr Med J. 2018 May 25;108(6):477-483. doi: 10.7196/SAMJ.2018.v108i6.12913. PMID: 30004327.
13. Dunbar R, Naidoo P, Beyers N, Langley I. High laboratory cost predicted per tuberculosis case diagnosed with increased case finding without a triage strategy. Int J Tuberc Lung Dis. 2017 Sep 1;21(9):1026-1034. doi: 10.5588/ijtld.17.0156. PMID: 28826453.
14. Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, Myer L, Abrams EJ, Walensky RP, Leroy V, Freedberg KA. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: a cost-effectiveness analysis. PLoS medicine. 2017 Nov 21;14(11):e1002446.
15. Dwommoh R, Sorsdahl K, Myers B, Asante KP, Naledi T, Stein DJ, Cleary S. Brief interventions to address substance use among patients presenting to emergency departments in resource poor settings: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2018 Jun 18;16:24. doi: 10.1186/s12962-018-0109-8. PMID: 29946229; PMCID: PMC6006568.
16. Evans D, Berhanu R, Moyo F, Nguweneza A, Long L, Fox MP. Can short-term use of electronic patient adherence monitoring devices improve adherence in patients failing second-line antiretroviral therapy? Evidence from a pilot study in Johannesburg, South Africa. AIDS and Behavior. 2016 Nov 1;20(11):2717-28.
17. Fatti G, Jackson D, Goga AE, Shaikh N, Eley B, Nachega JB, Grimwood A. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa. J Int AIDS Soc. 2018 Feb;21 Suppl 1(Suppl Suppl 1):e25041. doi: 10.1002/jia2.25041. PMID: 29485714; PMCID: PMC5978711.
18. Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, Walensky RP, Leroy V, Weinstein MC, Parker RA, Freedberg KA. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. The Journal of infectious diseases. 2016 Nov 1;214(9):1319-28.
19. Fraser I, Burger J, Lubbe M, Dranitsaris G, Sonderup M, Stander T. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Pharmacoeconomics. 2016 Apr;34(4):403-17. doi: 10.1007/s40273-015-0356-x. PMID: 26666639.
20. Gaziano T, Cho S, Sy S, Pandya A, Levitt NS, Steyn K. Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa. Health Aff (Millwood). 2015 Sep;34(9):1578-85. doi: 10.1377/hlthaff.2015.0351. PMID: 26355061; PMCID: PMC4816639.
21. Gaziano T, Abrahams-Gessel S, Surka S, Sy S, Pandya A, Denman CA, Mendoza C, Puoane T, Levitt NS. Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. Health Aff (Millwood). 2015 Sep;34(9):1538-45. doi: 10.1377/hlthaff.2015.0349. PMID: 26355056; PMCID: PMC4795815.
22. Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-effectiveness of community-based TB/HIV screening and linkage to care in rural South Africa. PLoS One. 2016 Dec 1;11(12):e0165614.
23. Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, Abbas UL. Cost-effGaziano T, Cho S, Sy S, Pandya A, Levitt NS, Steyn K. ectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Reviews of Infectious Diseases. 2016 May 18;63(4):539-47.
24. Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. BMC Infect Dis. 2016 Dec 1;16(1):726. doi: 10.1186/s12879-016-2064-3. PMID: 27905897; PMCID: PMC5131398.
25. Groessl EJ, Ganiats TG, Hillery N, Trollip A, Jackson RL, Catanzaro DG, Rodwell TC, Garfein RS, Rodrigues C, Crudu V, Victor TC. Cost analysis of rapid diagnostics for drug-resistant tuberculosis. BMC infectious diseases. 2018 Dec 1;18(1):102.
26. Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, Granich R. Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis. 2014 Oct;18(10):1159-65. doi: 10.5588/ijtld.13.0571. PMID: 25216828; PMCID: PMC4886505.
27. Haacker M, Fraser-Hurt N, Gorgens M. Effectiveness of and financial returns to voluntary medical male circumcision for HIV prevention in South Africa: an incremental cost-effectiveness analysis. PLoS medicine. 2016 May 3;13(5):e1002012.
28. Heffernan A, Barber E, Thomas R, Fraser C, Pickles M, Cori A. Impact and Cost-Effectiveness of Point-Of-Care CD4 Testing on the HIV Epidemic in South Africa. PLoS One. 2016 Jul 8;11(7):e0158303. doi: 10.1371/journal.pone.0158303. PMID: 27391129; PMCID: PMC4938542.
29. Hecht R, Hiebert L, Spearman WC, Sonderup MW, Guthrie T, Hallett TB, Nayagam S, Razavi H, Soe-Lin S, Vilakazi-Nhlapo K, Pillay Y, Resch S. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. Health Policy Plan. 2018 May 1;33(4):528-538. doi: 10.1093/heapol/czy018. PMID: 29529282; PMCID: PMC5894072.
30. Hontelez JA, Chang AY, Ogbuoji O, de Vlas SJ, Bärnighausen T, Atun R. Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness. AIDS. 2016 Sep 24;30(15):2341-50. doi: 10.1097/QAD.0000000000001190. PMID: 27367487; PMCID: PMC5017264.
31. Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, Williams A, Singh V, Thomas A. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):677-689. doi: 10.1080/14737167.2018.1507821. Epub 2018 Aug 23. PMID: 30073886.
32. Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, Hallett TB. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One. 2015 Jan 23;10(1):e0115511. doi: 10.1371/journal.pone.0115511. PMID: 25616135; PMCID: PMC4304839.
33. Jha S, Ismail N, Clark D, Lewis JJ, Omar S, Dreyer A, Chihota V, Churchyard G, Dowdy DW. Cost-effectiveness of automated digital microscopy for diagnosis of active tuberculosis. PloS one. 2016 Jun 20;11(6):e0157554.
34. Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1435-1442. doi: 10.5588/ijtld.18.0370. PMID: 30606315; PMCID: PMC6635914.
35. Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RG. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. PloS one. 2015 Dec 30;10(12):e0145796.
36. Kripke K, Opuni M, Schnure M, Sgaier S, Castor D, Reed J, Njeuhmeli E, Stover J. Age targeting of voluntary medical male circumcision programs using the Decision Makers’ Program Planning Toolkit (DMPPT) 2.0. PloS one. 2016 Jul 13;11(7):e0156909.
37. Kripke K, Chen PA, Vazzano A, Thambinayagam A, Pillay Y, Loykissoonlal D, Bonnecwe C, Barron P, Kiwango E, Castor D, Njeuhmeli E. Cost and Impact of Voluntary Medical Male Circumcision in South Africa: Focusing the Program on Specific Age Groups and Provinces. PLoS One. 2016 Jul 13;11(7):e0157071. doi: 10.1371/journal.pone.0157071. Erratum in: PLoS One. 2017 Jan 3;12 (1):e0169802. PMID: 27409079; PMCID: PMC4943592.
38. Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. Aids. 2016 Nov 28;30(18):2865-73.
39. Kuznik A, Habib AG, Munube D, Lamorde M. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. BMC health services research. 2016 Dec 1;16(1):304.
40. Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, Coetzee LM, Greene GS, Chiller TM, Vallabhaneni S, Long L, van Rensburg C, Govender NP. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS One. 2016 Jul 8;11(7):e0158986. doi: 10.1371/journal.pone.0158986. PMID: 27390864; PMCID: PMC4938608.
41. Lépine A, Nundy N, Kilbourne-Brook M, Siapka M, Terris-Prestholt F. Cost-Effectiveness of Introducing the SILCS Diaphragm in South Africa. PLoS One. 2015 Aug 21;10(8):e0134510. doi: 10.1371/journal.pone.0134510. PMID: 26295955; PMCID: PMC4546642.
42. Li X, Stander MP, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. BMC infectious diseases. 2015 Dec 1;15(1):566.
43. Lince-Deroche N, Fetters T, Sinanovic E, Devjee J, Moodley J, Blanchard K. The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa. PloS one. 2017 Apr 3;12(4):e0174615.
44. Lince-Deroche N, Constant D, Harries J, Kluge J, Blanchard K, Sinanovic E, Grossman D. The costs and cost effectiveness of providing second-trimester medical and surgical safe abortion services in Western Cape Province, South Africa. PloS one. 2018 Jun 28;13(6):e0197485.
45. Lince-Deroche N, van Rensburg C, Roseleur J, Sanusi B, Phiri J, Michelow P, Smith JS, Firnhaber C. Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa. PLoS One. 2018 Oct 11;13(10):e0203921. doi: 10.1371/journal.pone.0203921. Erratum in: PLoS One. 2019 Feb 12;14(2):e0212391. PMID: 30308014; PMCID: PMC6181291.
46. Lince-Deroche N, Phiri J, Michelow P, Smith JS, Firnhaber C. Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa. PLoS One. 2015 Nov 16;10(11):e0141969.
47. Long LC, Maskew M, T BRENNAN A, Mongwenyana C, Nyoni C, Malete G, Sanne I, Fox MP, Rosen S. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: A cost-effectiveness analysis of the RapIT randomized controlled trial. AIDS (London, England). 2017 Jul 17;31(11):1611.
48. Loveday M, Wallengren K, Reddy T, Besada D, Brust JCM, Voce A, Desai H, Ngozo J, Radebe Z, Master I, Padayatchi N, Daviaud E. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care. PLoS One. 2018 Apr 18;13(4):e0196003. doi: 10.1371/journal.pone.0196003. PMID: 29668748; PMCID: PMC5906004.
49. Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC health services research. 2017 Dec 1;17(1):87.
50. Manyema M, Veerman JL, Chola L, Tugendhaft A, Labadarios D, Hofman K. Decreasing the burden of type 2 diabetes in South Africa: the impact of taxing sugar-sweetened beverages. PLoS One. 2015 Nov 17;10(11):e0143050.
51. Manyema M, Veerman LJ, Tugendhaft A, Labadarios D, Hofman KJ. Modelling the potential impact of a sugar-sweetened beverage tax on stroke mortality, costs and health-adjusted life years in South Africa. BMC Public Health. 2016 May 31;16:405. doi: 10.1186/s12889-016-3085-y. PMID: 27240422; PMCID: PMC4886444.
52. Mash R, Kroukamp R, Gaziano T, Levitt N. Cost-effectiveness of a diabetes group education program delivered by health promoters with a guiding style in underserved communities in Cape Town, South Africa. Patient Educ Couns. 2015 May;98(5):622-6. doi: 10.1016/j.pec.2015.01.005. Epub 2015 Jan 20. PMID: 25641665.
53. Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health. 2016 Nov;4(11):e816-e826. doi: 10.1016/S2214-109X(16)30265-0. Epub 2016 Oct 6. PMID: 27720689; PMCID: PMC5527122.
54. Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017 Oct 26;12(10):e0186496. doi: 10.1371/journal.pone.0186496. PMID: 29073167; PMCID: PMC5658054.
55. Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, Churchyard G, Watts C, Vickerman P. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med. 2015 Sep 1;12(9):e1001869. doi: 10.1371/journal.pmed.1001869. PMID: 26327271; PMCID: PMC4556678.
56. Moodley N, Gray G, Bertram M. Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012. BMC Public Health. 2016 Dec 1;16(1):330.
57. Moodley N, Gray G, Bertram M. The case for adolescent HIV vaccination in South Africa: a cost-effectiveness analysis. Medicine. 2016 Jan;95(4).
58. Naidoo K, Grobler AC, Deghaye N, Reddy T, Gengiah S, Gray A, Abdool Karim S. Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):576-84. doi: 10.1097/QAI.0000000000000673. PMID: 26167618; PMCID: PMC4503368.
59. Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infect Dis. 2017 Apr 22;4(2):ofx081. doi: 10.1093/ofid/ofx081. PMID: 28680903; PMCID: PMC5490502.
60. Philipsen RH, Sánchez CI, Maduskar P, Melendez J, Peters-Bax L, Peter JG, Dawson R, Theron G, Dheda K, van Ginneken B. Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs. Sci Rep. 2015 Jul 27;5:12215. doi: 10.1038/srep12215. PMID: 26212560; PMCID: PMC4515744.
61. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, Siberry GK, Spiegel HM, Stringer JS, Chi BH. Cost-effectiveness of pre-exposure HIV prophylaxis during pregnancy and breastfeeding in Sub-Saharan Africa. Journal of acquired immune deficiency syndromes (1999). 2016 Aug 1;72(Suppl 2):S145.
62. Quaife M, Terris-Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne-Brook M, Mvundura M, Meyer-Rath G, Delany-Moretlwe S, Vickerman P. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018 Mar;21(3):e25064. doi:
63. Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb;16(1):43-54. doi: 10.1007/s40258-017-0352-8. PMID: 28980217.
64. Schnippel K, Michelow P, Chibwesha CJ, Makura C, Lince-Deroche N, Goeieman B, Mulongo M, Jordaan S, Firnhaber C. Cost-effectiveness of using the Cervex-Brush (broom) compared to the elongated spatula for collection of conventional cervical cytology samples within a high-burden HIV setting: a model-based analysis. BMC health services research. 2015 Jun 1;15(1):499.
65. Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, Hallett TB, Barnabas RV. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV. 2015 Apr;2(4):e159-68. doi: 10.1016/S2352-3018(15)00016-8. PMID: 25844394; PMCID: PMC4384819.
66. Tabana H, Nkonki L, Hongoro C, Doherty T, Ekström AM, Naik R, Zembe-Mkabile W, Jackson D, Thorson A. A Cost-Effectiveness Analysis of a Home-Based HIV Counselling and Testing Intervention versus the Standard (Facility Based) HIV Testing Strategy in Rural South Africa. PLoS One. 2015 Aug 14;10(8):e0135048. doi: 10.1371/journal.pone.0135048. PMID: 26275059; PMCID: PMC4537202.
67. Taylor C, Joolay Y, Buckle A, Lilford R. Prioritising allocation of donor human breast milk amongst very low birthweight infants in middle-income countries. Matern Child Nutr. 2018 Dec;14 Suppl 6(Suppl 6):e12595. doi: 10.1111/mcn.12595. PMID: 30592164; PMCID: PMC6865934.
68. Torborg A, Ryan L, Kantor G, Biccard BM. The pharmacoeconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after non-cardiac surgery. S Afr Med J. 2014 Jul 22;104(9):619-23. doi: 10.7196/samj.7654. PMID: 25212403.
69. Uthman RT, Sutton AJ, Jackson LJ, Uthman OA. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis. PloS one. 2018 Jan 23;13(1):e0191465.
70. van Elsland SL, van Dongen SI, Bosmans JE, Schaaf HS, van Toorn R, van Furth AM. Cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculous meningitis. Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1188-1195. doi: 10.5588/ijtld.18.0236. PMID: 30236187.
71. Vandormael, Alain & Boulware, David & Tanser, Frank & Bärnighuasen, Till & Stott, Katharine & de Oliveira, Tulio. Virologic monitoring can be a cost-effective strategy to diagnose treatment failure on first-line ART. Journal of acquired immune deficiency syndromes. 2016 71. 462-466. 10.1097/QAI.0000000000000870.
72. Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, McCarthy K, Churchyard G, Grant A, Sinanovic E. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. The Lancet Global Health. 2017 Jul 1;5(7):e710-9.
73. Volmink HC, Bertram MY, Jina R, Wade AN, Hofman KJ. Applying a private sector capitation model to the management of type 2 diabetes in the South African public sector: a cost-effectiveness analysis. BMC Health Serv Res. 2014 Sep 30;14:444. doi: 10.1186/1472-6963-14-444. PMID: 25265883; PMCID: PMC4263039.
74. Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD. The anticipated clinical and economic effects of 90–90–90 in South Africa. Annals of internal medicine. 2016 Sep 6;165(5):325-33.
75. Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. The Journal of infectious diseases. 2016 May 15;213(10):1523-31.
76. Walensky RP, Borre ED, Bekker LG, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Anglaret X, Freedberg KA, Paltiel AD. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Ann Intern Med. 2017 Nov 7;167(9):618-629. doi: 10.7326/M17-1358. Epub 2017 Aug 29. PMID: 28847013; PMCID: PMC5675810.
77. Watkins DA, Olson ZD, Verguet S, Nugent RA, Jamison DT. Cardiovascular disease and impoverishment averted due to a salt reduction policy in South Africa: an extended cost-effectiveness analysis. Health Policy Plan. 2016 Feb;31(1):75-82. doi: 10.1093/heapol/czv023. Epub 2015 Apr 3. PMID: 25841771; PMCID: PMC4724166.
78. Williams BG, Gupta S, Wollmers M, Granich R. Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study. Lancet Public Health. 2017 May;2(5):e223-e230. doi: 10.1016/S2468-2667(17)30066-X. Epub 2017 Apr 10. PMID: 29253488.
79. Yu W, Li C, Fu X, Cui Z, Liu X, Fan L, Zhang G, Ma J. The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling. PLoS One. 2014 Jul 23;9(7):e102872. doi: 10.1371/journal.pone.0102872. PMID: 25055039; PMCID: PMC4108380.

**EGYPT: 16 studies**

1. Abd Elrazek MA, Eid KA, Abd Elhalim A, Abd UM, El-Sherbiny SM, Bilasy SE. Screening esophagus during routine ultrasound: medical and cost benefits. European journal of gastroenterology & hepatology. 2015 Jan 1;27(1):8-12.
2. Abdel-Raheem TA, Méabed EM, Nasef GA, Abdel Wahed WY, Rohaim RM. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. Journal of Dermatological Treatment. 2016 Sep 2;27(5):473-9.
3. Ashoush N. Economic evaluation of imipenem-cilastatin versus doripenem in ventilator-associated pneumonia in Egypt. 2017
4. El Sabaawy D, El‐Haggar S, El‐Bahrawy H, Waked I, El‐Said H. A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients. Apmis. 2015 Jun;123(6):482-9.
5. El-Ghitany EM. Cost-effectiveness of EGCRISC application versus hepatitis C virus mass screening in Egypt. J Infect Public Health. 2019 May-Jun;12(3):442-444. doi: 10.1016/j.jiph.2018.08.004. Epub 2018 Sep 13. PMID: 30220579
6. El-Hamamsy MH, Elsisi GH, Eldessouki R, Elmazar MM, Taha AS, Awad BF, Elmansy H. Economic evaluation of the combined use of warfarin and low-dose aspirin versus warfarin alone in mechanical valve prostheses. Applied health economics and health policy. 2016 Aug 1;14(4):431-40.
7. El-Khamery AA, Mohamed AI, Swify HE, Mohamed AI. Cost-effectiveness of glaucoma management with monotherapy medications in Egypt. Journal of Advanced Pharmaceutical Technology & Research. 2017 Jan;8(1):25.
8. El-Saiedi SA, El Sisi AM, Mandour RS, Abdel-Aziz DM, Attia WA. Cost-effectiveness analysis of different devices used for the closure of small-to-medium-sized patent ductus arteriosus in pediatric patients. Annals of pediatric cardiology. 2017 May;10(2):144.
9. Elsisi GH, Aburawash A, Waked E. Cost-effectiveness analysis of new HCV treatments in Egyptian cirrhotic and non-cirrhotic patients: a societal perspective. Value in health regional issues. 2017 Sep 1;13:7-15.
10. Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Medical oncology. 2015 Jan 1;32(1):432.
11. Estes C, Abdel‐Kareem M, Abdel‐Razek W, Abdel‐Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Alimentary pharmacology & therapeutics. 2015 Sep;42(6):696-706.
12. Hamdy Elsisi G, Nada Y, Rashad N, Carapinha J. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt. J Med Econ. 2019 Feb;22(2):163-168. doi: 10.1080/13696998.2018.1552432. Epub 2018 Dec 13. PMID: 30479174.
13. Harwan WA, Abbassi MM, El-Attar MM, Farid SF. Pharmacoeconomic study of antibiotics used in the treatment of lower respiratory tract infections in ICU patients: A case study in an Egyptian hospital. Bulletin of Faculty of Pharmacy, Cairo University. 2014;52:135-44.
14. Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D. The accuracy and cost‐effectiveness of hepatitis C core antigen assay in the monitoring of anti‐viral therapy in patients with chronic hepatitis C genotype 4. Alimentary pharmacology & therapeutics. 2015 Aug;42(3):307-18.
15. Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA, Soliman AS. Cost-effectiveness model for hepatitis C screening and treatment: implications for Egypt and other countries with high prevalence. Global public health. 2015 Mar 16;10(3):296-317.
16. Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Freikha SA, Hoestlandt C, Lara C, Hajjeh R. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015 May 7;33:A182-91.